Company ProfilePremium

Groupe Bruxelles Lambert SA

Company Profile Analysis

Ticker: GBLB.BR

ESOMAR 23 Corporate BadgeISO Certifications Badge
Groupe Bruxelles Lambert SA - Company showcase

Year Founded & Workforce

1902

Groupe Bruxelles Lambert SA logo

Groupe Bruxelles Lambert SA Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Groupe Bruxelles Lambert SA Overview

GBL is one of continental Europe's oldest and largest listed investment holding companies. It is controlled by the Frère (Belgium) and Desmarais (Canada) families through Parjointco, which has a 47.8% voting interest. With a NAV of €13.1bn at June 2026 and an A1 Moody's rating, GBL is pivoting from a legacy portfolio of minority stakes in large European listed companies (SGS, Pernod Ricard, adidas, Imerys) towards controlled or co-controlled private companies. The private push is concentrated in healthcare (Affidea, Sanoptis, Rayner, and Recordati pending) and business services (BUKO). Under the November 2024 Strategic Update and new Managing Director Johannes Huth (ex-KKR), GBL targets three things:

  • double-digit annual TSR;

  • a stable €5.125 dividend per share (c.6–7% yield);

  • opportunistic buybacks, funded by €5bn+ of disposals.

The equity story has two parts. One is closing a persistent holding-company discount, which was 27.9% at end-2025. The other is whether GBL can prove private-equity-style value creation at scale while carrying zero net leverage.


Company's own description

GBL describes itself as an established investment holding company with over seventy years of stock-exchange listing. It calls itself a leading and active investor in Europe, focused on long-term value creation and backed by a stable family shareholder base. Its purpose statement, "delivering meaningful growth", promises shareholders attractive returns through three channels: growth in NAV per share, a sustainable dividend and share buybacks (H1 2026 press release, "About GBL").

Business model

GBL earns returns from four sources:

  1. Dividends from listed and private holdings. These are the core of "cash earnings": €367m of net dividends out of €381m of FY2025 cash earnings.

  2. Capital gains crystallised on disposals. Under IFRS 9 these do not pass through the consolidated net result for fair-value-through-OCI holdings. Examples: €164m on SGS and €(98)m on Umicore in FY2025.

  3. Value creation in private assets, marked to fair value quarterly under IPEV guidelines. FY2025 value creation from direct private assets was +€641m.

  4. Treasury income on gross cash: €51m of income on gross cash in FY2025.

The holding has minimal cost (other operating expenses within cash earnings were €(55)m in FY2025). It funds itself with institutional bonds, a convertible bond into GBL shares, and committed undrawn credit lines (€2.45bn, maturing 2030).

Revenue model (product vs service vs subscription vs licensing)

Consolidated turnover component, FY2025 (EUR Mn)NatureAmount% of consolidated turnover
ImerysIndustrial minerals products3,383.754.4
AffideaHealthcare services (diagnostics/outpatient)1,248.020.1
SanoptisHealthcare services (ophthalmology)773.312.4
CanyonConsumer products (D2C bicycles)771.712.4
GBL Capital / Sienna IMAsset management fees and consolidated funds45.00.7
Total—6,221.7100.0

This framework does not apply directly to GBL. At the holding level, "revenue" consists of dividends, interest and realised gains. On a consolidated IFRS basis, turnover (€6,222m in FY2025) is the sales of controlled companies:

Source: GBL FY2025 Results, Appendix B.4 (IFRS segment table). On this view the consolidated mix is roughly 54% product (Imerys), 33% services (healthcare), 12% D2C product (Canyon) and about 1% fees. BUKO (services, c.€230m revenue per Manda.be) has been consolidated from July 2026.

Value-chain position, customers and end-markets

GBL sits at the capital-allocation layer of the value chain. Its customers are its shareholders and, indirectly, the end-customers of its portfolio companies. End-market exposure by asset at end-2025 and mid-2026:

Healthcare services: diagnostic imaging, laboratory, outpatient and cancer care (Affidea); ophthalmic surgery and diagnostics (Sanoptis).

MedTech: intraocular lenses and ophthalmic consumables (Rayner).

Specialty pharma: rare diseases and primary/specialty care (Recordati, pending).

Testing, inspection and certification (TIC): SGS.

Premium spirits: Pernod Ricard.

Sportswear: adidas.

Industrial specialty minerals: Imerys.

Customer-experience outsourcing: Concentrix.

Premium bicycles: Canyon.

Mobile gaming: Voodoo.

Leisure parks: Parques Reunidos.

Temporary traffic management: BUKO.

Hygiene products: Ontex.

Independent characterisation

GBL is in mid-transformation from a passive "Belgian blue-chip conglomerate" into a hybrid closer to a family-backed private-equity firm with permanent capital. That model resembles Investor AB's Patricia Industries or Exor's private-asset arm. The 2024–2027 plan has three pillars:

  • simplification, with over €5bn of disposals achieved by H1 2026;

  • concentration in controlled or co-controlled direct private assets, which rose from 32% of the portfolio at end-2025 to 37% at Q1 2026 before the BUKO and Recordati investments;

  • capital return.

The key analytical tension is valuation and disclosure. Private assets are carried at manager marks, while the market applies a 20–30% discount. The listed legacy book has also been a persistent drag on NAV: Pernod Ricard's fair value fell €619m in FY2025 and adidas €430m.

Strategy

Stated strategy (2024–2027 mid-term plan, Strategic Update of 7 Nov 2024)

GBL's FY2025, Q1 2026 and H1 2026 presentations group the strategy into three priorities:

  1. Portfolio simplification: €5bn of disposals targeted over 2024–2027. More than €5bn had been achieved by H1 2026: adidas €1.7bn (2024); GBL Capital €1.7bn, SGS €0.8bn and Umicore €0.3bn (2025); Umicore €0.3bn, Concentrix €0.1bn and non-core €0.2bn (H1 2026).

  2. Focus on direct private assets: priority to controlled or co-controlled investments in growing markets, and an increased weight of direct private assets. Test-Achats (May 2025) reports an aim of roughly 50% listed / 50% private by 2027.

  3. Attractive returns to shareholders: double-digit annual TSR, a sustainable dividend and share buybacks.

Purpose statement: "Delivering meaningful growth".

Medium-term targets and guidance

TargetStatus (latest)
Double-digit annual TSR23.2% (FY2025); 17.5% (12 months to June 2026)
€5bn disposals 2024–2027Exceeded by H1 2026
Dividend per share€5.125 for FY2025 (paid 18 May 2026); to be held stable "for the foreseeable future"
Share buybacksOpportunistic; eighth envelope 30.4% executed at 10 Mar 2026; 3.4m shares cancelled May 2026
LTVBelow historical 10% upper limit; currently 0.0%

Strategic initiatives in the last 24 months

DateInitiativeDetail
Nov 2024Strategic UpdateNew plan; dividend reset to €5.00 (+82%)
Mar–May 2025Governance transitionHuth as Managing Director, Gallienne as Chairman
Q1 2025SGS partial sale€0.8bn
Oct 2025Affidea €150m equity injectionGrowth acceleration
Q4 2025GBL Capital secondary sale and run-off€1.7bn proceeds; €0.6bn of unfunded commitments transferred
Dec 2025 – Feb 2026Sienna IM disposalExit of third-party asset management
2,025Canyon reorganisationCost and organisational adaptation
Jan 2026Team build-outTwo Investment Partners; Technology added as a sector
Feb–May 2026Rayner€0.5bn, 45% co-control
Apr–Jul 2026BUKOc.€0.5bn, controlling stake; business-services platform
May 2026 →Recordati take-private with CVCGBL's largest healthcare investment to date
Jan and Aug 2026Balance-sheet financingTwo €500m bonds (10-year 3.75%; 8-year)
OngoingGBL ACTSolidarity / philanthropic engagement programme (AGM 2026 agenda item)

ESG and sustainability commitments

Science-based GHG targets were validated by SBTi in January 2022 (GBL FY2021 Results). GBL publishes an ESRS-aligned Sustainability Statement as Volume 2 of its Annual Report 2025, with limited assurance by PwC.

Products & Services

For an investment holding, the "product catalogue" is the investment portfolio. Each holding is profiled below.

Listed assets (NAV at 31 Dec 2025)

HoldingBusinessGBL stake (% capital)Share price 31-Dec-25 (EUR)NAV EUR Mn 31-Dec-25NAV EUR Mn 31-Dec-24FY2025 TSR (%)Notes
SGSWorld leader in testing, inspection and certification14.3497.552,7253,5014.9€0.8bn partial sale Q1 2025; 5.6% organic growth in 2025, 24 acquisitions including Applied Technical Services (US)
Pernod RicardGlobal #2 spirits and wines6.8373.101,2601,879-29.2Tariff and inventory headwinds; €1bn efficiency plan FY26–FY29; targets 3–6% organic growth FY27–FY29
ImerysWorld #1 specialty minerals (consolidated at 55%)54.7223.941,1131,311-11.02025 revenue €3.385bn; adjusted EBITDA €546m; €467m goodwill impairment; Project Horizon targets €50–60m of savings
adidasGlobal #2 sportswear3.53169.051,0751,496-28.02025 brand sales +13% currency-neutral; operating margin 8.3%; up to €1bn buyback in 2026
UmicoreMaterials technology and recycling7.96 (exited Feb 2026)17.9035139185.3Fully exited 25 Feb 2026 (c.19.6m shares, €0.3bn)
ConcentrixCX outsourcing (Webhelp combination)14.0935.39 (USD converted)314371-13.0€0.1bn disposed in H1 2026
OntexPersonal hygiene products19.984.9081138-41.6Small legacy position
TotalEnergiesIntegrated energy0.0155.5971412.0Residual
GEAFood processing machinery0.0757.806523.3Residual

Source: GBL FY2025 Results, Appendix A.1 and A.2; Imerys FY2025 release. At Q1 2026, SGS was c.44% of listed NAV, Pernod 19%, Imerys 17% and adidas 15% (Kalkine, citing the GBL Q1 2026 report).

Direct private assets

AssetDescriptionEntryGBL stakeNAV 31-Dec-25 (EUR Mn)Key operating facts
AffideaPan-European provider of advanced diagnostics, outpatient services, lab testing and cancer careJuly 202299.16%2,140FY2025 sales €1,224m (+17%, +6% organic); 418 locations; 35.0m examinations; 18 acquisitions in 2025 (IHZD pathology and Uroviva urology in Switzerland); €150m equity injection Oct 2025; LabPoint (Switzerland) acquired early 2026; AI roll-out across clinics
SanoptisEuropean leader in ophthalmology services (surgery and diagnostics)July 202284.34% (69.87% fully diluted)1,105FY2025 sales €813m (+18%, +8% organic); 468 locations; 959 doctors; 5,207 employees; 3.7m treatments; present in Switzerland, Germany, Spain, Italy, Austria and Greece
CanyonWorld's largest direct-to-consumer manufacturer of premium bikes (Koblenz, Germany)March 202152.35%267FY2025 sales €738m (-6%); EBITDA -34%; e-MTB quality suspensions (Q4 2024) completed; organisational restructuring; new Koblenz e-bike store in 2026
VoodooLeading mobile game publisher by downloads (France)2021 (minority)14.93%314FY2025 sales €689m (+11%)
Parques ReunidosEuropean leisure-park operator2017 (minority; private since 2019)23.00%281US business sold (March 2025 announcement); FY2025 sales €549m (-36% reported, broadly stable like-for-like); refinanced and paid a dividend
Rayner (new)UK-based maker of intraocular lenses (IOLs), ophthalmic consumables (OMIDRIA, Ophteis OVDs), SOPHI phaco platform and digital tools; operates in 80+ countriesSigned 9 Feb 2026; closed 28 May 202645% co-control with CVC€0.5bn equity (held at cost)Galaxy spiral IOL launch expected Q4 2026; EMV and EMV toric lenses recently approved in North America (CVC; Insight News)
BUKO Group (new)Temporary traffic management (TTM): design and planning, permits, deployment and collection of signage, on-site management, digital traffic solutionsSigned 23 Apr 2026; closed 8 Jul 2026Majority/controllingc.€0.5bn equity (Manda.be: €500m)Founded in the Netherlands in 1991; c.1,000 employees; operations in the Netherlands, Sweden, the UK and Germany; c.€230m revenue; bolt-ons include Keltic (London), Road Traffic Solutions and BVT Bremer Verkehrstechnik; Beverwijk HQ
Recordati (pending)Italian specialty pharma: rare diseases (e.g. Isturisa for Cushing's), specialty and primary care, self-medication, APIsTender announced 22 May 2026 (with CVC Fund IX)Co-control with CVC; GBL already holds c.3.25% (Mergermarket)Equity commitment up to c.10% of 31-Mar-26 NAV (Zonebourse), i.e. c.€1.3bn2025 revenue €2.62bn; Q1 2026 revenue €713.4m (+4.9%); c.4,700 employees; offer raised to €53/share in Oct 2026

Non-core asset classes

AssetDescriptionNAV 31-Dec-25 (EUR Mn)Status
GBL CapitalFunds (e.g. ICONIQ, Human Capital, 468 Capital, Sagard, Griffin, Kartesia, Backed) and co-investments (Flora Food Group €224.6m, Proalpha €71.9m, Commure €39.9m, Transcarent €17.7m), Sienna-branded funds1666 (of which cash and working capital €590.6m)Large secondary sale (€1.7bn proceeds; €0.5bn deferred 12 months); no new commitments; remaining unfunded commitments €238m
Sienna Investment ManagersThird-party asset management (Sienna Gestion, Sienna Private Credit, Sienna Real Estate)61Sale agreements signed Dec 2025 and Feb 2026; FY2025 net economic result €(69)m

Source: GBL FY2025 Results, Appendix A.4–A.5: ### Pricing model

Not applicable at holding level. GBL charges no fees to its own shareholders. Sienna IM earned €127m in FY2025 revenues, including €11m of fees from GBL Capital, before its disposal.

Financial Narrative

Holding-company key performance indicators (primary metrics)

Sources: FY2021: GBL FY2021 Results (10 Mar 2022): - FY2022: GBL FY2022 Results (9 Mar 2023).

  • FY2023: GBL FY2023 Results, including economic presentation (cash earnings €414.1m, net result €1,723.2m, basic EPS €12.28; FY2022 EPS €(3.99)).

  • FY2024–FY2025: GBL FY2025 Results.

  • Discounts for 2021–2023 are computed as 1 − price/NAV per share; 2024–2025 are as reported by GBL.

Leverage indicators (partial history)

Sources: GBL FY2021 Results; GBL FY2025 Results Appendix B.2; RTTNews and GBL H1 2026 release. The FY2022 LTV was 15.7% at end-September 2022 before the pro-forma Holcim forward sales (GBL FY2022 release).

IFRS consolidated figures (template metrics, heavily qualified)

Sources: GBL FY2025 Results Appendix B.4; GBL H1 2025 economic presentation; RTTNews and Simply Wall St (H1 2026 sales €3,359.3m).

Gross profit, operating income, EBITDA and IFRS margins at group level are not presented by GBL and would be economically misleading. They mix Imerys's industrial P&L with holding-level fair-value effects. FY2025 consolidated EBITDA is therefore "not publicly disclosed" as a GBL KPI.

The FY2025 IFRS lines allow a rough proxy. Turnover €6,221.7m less raw materials €1,906.9m, employee expenses €1,920.7m and other operating expenses €1,359.9m gives an operating-company EBITDA proxy of about €1,034m. This is an analyst calculation, not a company figure. Depreciation was €606.0m and impairments €545.6m.

Cash earnings composition

Source: GBL FY2025 Results, Appendix B.3: ### Cash flow: notes and sources

Source: GBL FY2025 Results, Appendix B.1: "Free cash flow" in the conventional sense is not a GBL metric. Cash earnings minus the dividend paid was about €(284)m in FY2025. The dividend, at €5.125 per share on c.120m shares outstanding net of treasury, costs c.€615–680m a year, which is above recurring cash earnings. The gap is funded by disposals. This is a structural point for Section 22.

Shareholder returns history

Sources: GBL FY2021, FY2022, FY2023 results; Power Corporation 2023 GBL page (€816m buybacks, €402m dividends in 2023); GBL FY2025 Results. H1 2026 cash returns totalled €773m (dividend plus buybacks; GBL H1 2026).

Trend commentary

NAV erosion (2021–2025). NAV fell from €22.5bn to €14.0bn, and NAV per share from €143.91 to €105.37 (−27%). Four forces drove this:

  1. the 2022 market drawdown (−19% NAV per share);

  2. persistent de-rating of the consumer holdings, with Pernod Ricard −33% and adidas −28% in fair value in FY2025 alone;

  3. distributions and buybacks that shrink absolute NAV;

  4. GBL Capital write-downs on the 2025 secondary sale, with €(381)m of IFRS result contribution.

Inflection points.

  • 2023: the Webhelp–Concentrix deconsolidation produced a €1.29bn gain and the record €1,723m net result.

  • 2024: the dividend was reset to €5.00.

  • 2025: GBL moved to net cash, and the discount narrowed from 41.7% to 27.9% as the new strategy gained credibility.

Cash earnings. These fell from €474m (2021) to €336m (2024) as dividend-paying listed stakes were sold and the Concentrix note was monetised. They recovered to €381m in 2025 on treasury income (€51m from gross cash) and the GBL Capital dividend (€89m). H1 2026 cash earnings of €296m (H1 2025: €320m) show the dilutive effect of selling dividend payers (SGS, Umicore) to buy growth assets, which pay no dividend.

IFRS volatility. The consolidated net result swings with Imerys impairments, GBL Capital mark-to-market and deconsolidation gains. It is not a reliable signal of underlying value creation.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Asset class (EUR Mn)

Asset class (EUR Mn)FY2021FY2022FY2023FY2024FY2025

Listed assets NAV (EUR Mn)

16,93312,450—9,1056,931

Direct private assets NAV (EUR Mn)

———3,3054,106

GBL Capital NAV (EUR Mn)

—2,5352,9512,7431,666

Sienna Investment Managers NAV (EUR Mn)

———13761

Total portfolio (EUR Mn)

22,71319,535—15,29012,765

Asset class mix (% of portfolio)

Asset class mix (% of portfolio)FY2025Q1 2026

Listed assets

5452

Direct private assets

3237

Non-core (GBL Capital and Sienna IM)

1410

Ifrs Segment, FY2025 Details

IFRS segment, FY2025 (EUR Mn)TurnoverPre-tax profit from consolidated operationsProfit attributable to group

Holding

0

71.8 (investing activities)

71.5

Imerys

3,383.7-381.5-224.8

Canyon

771.7-25.1-5.5

Affidea

1,248.074.353.7

Sanoptis

773.3-97.3-70.9

GBL Capital / Sienna IM

45.0

-4.6 (operating); -141.9 (investing)

-449.4

Group total

6,221.7

-434.2 (operating)

-625.4

Segment Revenue

MetricAffideaSanoptisCanyonTotal

Sales FY2025 (EUR Mn)

1,2248137382,775

Sales growth (%)

1718-610

Organic growth (%)

68-62

EBITDA growth (%)

3518-3420

GBL ownership (%)

99.1684.3452.35—

NAV 31 Dec 2025 (EUR Mn)

2,1401,1052673,512

MoIC (x)

1.91.50.7—

Key Financials and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Net asset value (EUR Mn)

22,50117,77516,67115,68114,035

NAV per share (EUR)

143.91116.18113.64113.30105.37

Year-end share price (EUR)

98.1674.5871.2266.0575.95

Discount to NAV (%)

31.835.837.341.727.9

Cash earnings (EUR Mn)

474416414336381

Consolidated net result, group share (EUR Mn)

279-5851,723132-625

Basic EPS (EUR)

1.83-3.9912.280.99-4.94

Dividend per share for the year (EUR)

2.752.752.755.005.125

Gross cash excl. treasury shares (EUR Mn)

2,2931,3971,0802,6062,393

Key Financials and Margin Analysis (%)

MetricFY2021FY2024FY2025H1 2026

Net cash / (net debt) (EUR Mn)

-990-460333

not disclosed in retrieved release (LTV 0.0%)

Loan to value (%)

4.33.00.00.0

Gross debt (EUR Mn)

—3,0702,061—

Liquidity profile (EUR Mn)

—5,0564,843

c.4600

Undrawn committed credit lines (EUR Mn)

——2,450

c.2500

Key Financials

MetricFY2024FY2025H1 2025H1 2026

Consolidated turnover (EUR Mn)

6,055.76,221.7—3,359.3

Consolidated profit for the period, total (EUR Mn)

63.2-833.6——

Net result, group share (EUR Mn)

132.3-625.444.053.5

Cash earnings (EUR Mn)

336.2381.3320.2296

Components

Component (EUR Mn)FY2024FY2025

Net dividends from investments

388.9367.4

Interest income (expenses)

-9.918.2

Other financial income (expenses)

10.851.0

Other operating income (expenses)

-55.0-55.1

Gains on disposals

1.60.0

Taxes

-0.1-0.3

Cash earnings total

336.2381.3

Dividend received by source (EUR Mn)

Dividend received by source (EUR Mn)FY2024FY2025

SGS

125.698.1

GBL Capital

71.589.3

Pernod Ricard

81.081.0

Imerys

62.667.4

adidas

6.310.8

Concentrix

9.510.1

Umicore

31.49.8

TotalEnergies

0.70.7

Total

388.9367.4

Financial Analysis

ItemFY2025

Opening net debt

-460.2

Cash earnings

381.3

Dividend paid for FY2024

-665.7

Investments (total)

-545.5

— of which GBL share buybacks

-334.9

— of which Affidea

-149.0

— of which Canyon

-19.8

— of which Sanoptis

-16.7

— of which SGS (scrip) / adidas

-25.1

Divestments / distributions

2,397.3

— of which GBL Capital net distributions

1,293.3

— of which SGS

772.1

— of which Umicore

299.3

Other (timing, LTIP/carry revaluation)

-774.4

Closing net cash

332.8

Dividends & Capital Returns

MetricFY2021FY2022FY2023FY2025

Share buybacks (EUR Mn)

407643816335

Dividends paid in year (EUR Mn)

——402666

Financial Analysis (FY2025 value)

RatioFY2025 valueComment

Return on NAV per share (NAV/share change + dividend)

c.-2.6% (105.37 − 113.30 + 5.00 paid = −2.93 on 113.30)

Analyst calculation

TSR (company-reported)

23.2% (FY2025); 17.5% (12 months to June 2026)

Rerating-driven (discount narrowed 1,378 bps)

ROE (IFRS)

Negative (net result €(625)m)

—

ROA, ROIC, asset turnover, cash conversion cycle

Not meaningful / not publicly disclosed for the holding

—

Current ratio

Not publicly disclosed in retrieved sources

—

Debt / equity

Gross debt €2,061m vs NAV €14,035m = 14.7% (FY2025)

NAV used as an equity proxy

Net debt / EBITDA

Not applicable (net cash)

—

Loan to value

0.0% (FY2025 and H1 2026)

Upper limit historically 10%

Interest coverage (cash)

Net dividends €367m vs bond/exchangeable interest €52m ≈ 7.1x

Analyst calculation from FY2025 Results

Weighted average debt maturity

4.1 years (Dec 2025) vs 3.6 (Dec 2024)

Extended by 2026 bonds

Holding Details

HoldingPrimary geographies

Affidea

Pan-European (418 locations). Switzerland is significantly expanded (IHZD, Uroviva, LabPoint). Hungary is being disposed of: 2025 reported sales exclude Hungary, and growth excluding Hungary exceeded 20%

Sanoptis

Switzerland and Germany (core), plus Spain (4 centres), Italy (7), Austria (5) and Greece (4)

Canyon

Europe (largest market by far); Asia and US subdued, with US tariff uncertainty

BUKO

Netherlands, Sweden, UK (expanded via Keltic in London), Germany

Rayner

UK HQ; 80+ countries; North American expansion; Asia and Latin America growth

Recordati

Global specialty pharma (Italy HQ); rare-disease franchise global

SGS

Global TIC; North American presence doubled via Applied Technical Services (SGS target of doubling North American sales is 80% achieved)

Parques Reunidos

Europe-only after the 2025 US disposal

Imerys

Global industrial minerals (EMEA, Americas, APAC)

Share Price and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Year-end share price (EUR)

98.1674.5871.2266.0575.95

Dividend per share for fiscal year (EUR)

2.752.752.755.005.125

Dividend yield on year-end price (%)

2.83.73.97.66.7

NAV per share (EUR)

143.91116.18113.64113.30105.37

Share Price & Returns

HorizonPerformanceSource

YTD 2026 (to ~mid-Oct)

c.+8.6% price (€75.95 → c.€82.5, eToro, Oct 2026)

Analyst calculation; date-sensitive

1-year TSR

17.5% (June 2025 → June 2026, company-reported); c.13.9% (Simply Wall St, Aug 2026)

GBL H1 2026; Simply Wall St

3-year

Price from €71.22 (YE2023) to c.€82.5: c.+16% before dividends

Analyst calculation

5-year total return

c.5.8% cumulative (Simply Wall St, Aug 2026)

Third-party

52-week range

c.€71.60–€85.25 (TipRanks, Frankfurt line)

Third-party

Long-run

Annualised TSR 6.4% from 2012 to 30 Sept 2024 vs 9.2% for the Stoxx Europe 50 (GBL website, 2024)

GBL

Valuation Snapshot

MetricValue

Price / NAV per share

c.0.82x (€82.5 / €100.77 at June 2026), a c.18% discount; 0.72x at YE2025 (27.9% discount)

Price / sales (consolidated)

c.1.4x (Simply Wall St, Aug 2026)

Price / book (IFRS)

c.0.72x (Fintel, July 2026)

Dividend yield

c.6.2% at €82.5 (€5.125 / €82.5)

Analyst consensus

TipRanks labels the stock "undervalued" without a disclosed target

Credit Ratings

AgencyRatingOutlookDate

Moody's

A1

Stable

Confirmed June 2026

Capital Instruments

Instrument (EUR Mn)31-Dec-202431-Dec-2025

Institutional bonds

2,0001,500

Exchangeable bonds into Pernod Ricard shares

5000

Convertible bonds into GBL shares

500500

Other

7061

Gross debt

3,0702,061

Analyst Conclusions

Management guidance

GBL reiterates double-digit annual TSR, driven by NAV-per-share growth, a stable €5.125 dividend and ongoing buybacks (H1 2026; RTTNews). It also commits to continued portfolio simplification and to raising the share of controlled or co-controlled direct private assets. It provides no earnings guidance, which is customary for holdings.

Bull case

  1. Discount compression has room to run. It narrowed from 41.7% to 27.9% in 2025 and to roughly 18% by October 2026. Continued buybacks (8% treasury shares), cancellations and proof of private-asset value could move GBL toward the low-teens discounts of best-in-class peers.

  2. The healthcare franchise compounds. Affidea (+17% sales, +35% EBITDA in FY2025), Sanoptis (+18% sales) and Rayner (Galaxy launch in Q4 2026, US growth) make up a growing share of NAV. Recordati adds a high-margin rare-disease asset bought alongside an incumbent controller with deep knowledge of the company.

  3. Firepower without leverage. LTV of 0.0%, €4.6bn of liquidity and an A1 rating allow counter-cyclical deployment and buybacks at the same time.

Bear case

  1. NAV per share keeps falling. It went from €143.91 (2021) to €100.77 (H1 2026), and the legacy consumer stakes (Pernod, adidas) and Imerys remain exposed to tariffs and industrial weakness.

  2. The dividend outruns recurring income. FY2025 cash earnings were €381m against a €666m dividend paid. H1 2026 cash earnings fell as dividend payers were swapped for non-dividend private assets, so the payout depends on continued disposals.

  3. Deal-price discipline is in question. The Recordati price was raised under activist pressure. Two co-controlled CVC assets concentrate counterparty and exit-timing risk. Canyon (0.7x MoIC) shows that private-asset marks can disappoint.

Catalysts and monitorables (next 12 months)

Recordati tender outcome: acceptance closes 23 October 2026; payment 2 November 2026. Watch whether the 66.67% threshold is met or waived, the delisting route, and GBL's final equity cheque.

Q3 2026 results: on 5 November 2026: NAV per share, cash earnings, and the first BUKO contribution.

FY2026 results (around March 2027): dividend confirmation at €5.125, value-creation marks for Rayner and BUKO after the 12-month cost-hold period, and disclosure on the remaining Concentrix and GBL Capital positions.

Rayner Galaxy IOL launch: (expected Q4 2026).

  • Pernod Ricard tariff and recovery trajectory; adidas growth; Imerys Project Horizon savings.

  • Closing of the Sienna Gestion and Sienna Private Credit sales.

  • Pace of buybacks and the next share cancellation at the 2027 EGM.

  • Any update to the mid-term plan as the 2024–2027 horizon nears its end, including portfolio-mix targets.

Analyst verdict

GBL in late 2026 is a credible but unfinished turnaround. The new leadership has done the easy and necessary part well, and quickly:

  • more than €5bn of disposals ahead of the 2027 deadline;

  • the exit from distracting third-party asset management;

  • a net-cash balance sheet with an A1 rating;

  • a dividend reset that now yields about 6%.

The market has rewarded this. The discount to NAV has roughly halved from its late-2024 peak, and twelve-month TSR is in double digits, as promised.

The hard part is now under way. GBL has committed about €2.3bn to Rayner, BUKO and Recordati, with more possible. That capital must compound at private-equity-like rates to reverse a multi-year decline in NAV per share. The early evidence is mixed. Affidea and Sanoptis demonstrate real buy-and-build skill (1.9x and 1.5x MoIC). Canyon shows how consumer cyclicality can hurt a direct-ownership model. The decision to raise the Recordati price, despite a waivable acceptance threshold, will be read as a test of discipline. The structural mismatch between recurring cash earnings and a €5.125 dividend also means the payout is effectively funded by realisations.

Downside is cushioned by a clean balance sheet, family sponsorship, a high yield and a still-meaningful discount of about 18%. Upside depends on evidence over the next four to six quarters that the private portfolio, now heavily weighted to European healthcare, generates mark-to-market and eventually cash value creation that offsets volatility in the residual listed book. The key monitorables are three:

  • NAV per share growth, ex-dividend, turning positive on a trailing twelve-month basis;

  • the first value-creation marks on Rayner and BUKO;

  • the execution and pricing outcome of Recordati.

If these line up, a further narrowing of the discount toward peer levels is plausible. If they do not, GBL risks reverting to a high-yield, low-growth holding whose discount re-widens.


Data gaps flagged (not publicly disclosed in sources retrieved):

  • holding-level headcount;

  • detailed executive compensation;

  • full board roster with independence and committee data;

  • top-10 institutional holders;

  • geographic revenue split;

  • FY2021–FY2023 consolidated turnover and IFRS margins;

  • FY2022–FY2023 net debt;

  • FY2024 buyback amount;

  • S&P and Fitch ratings;

  • ESG ratings;

  • peer quantitative benchmarks;

  • the bond maturity ladder;

  • the coupon on the August 2026 bond.

These should be completed from GBL's Annual Report 2025 (Vol. 1 and 2) and the Half-year Report 2026 PDFs.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenurePrior roles / backgroundNotes

Johannes Huth

Managing Director (Administrateur-Délégué; effectively CEO)

Since 2 May 2025

25 years at KKR (from 1999), most recently Partner and Chairman of KKR EMEA, then Senior Advisory Partner (2024); Investcorp management committee 1991–1999; Salomon Brothers M&A 1986–1991 (London, New York)

Board member of Imerys, Axel Springer SE and Marshall Wace; chairs LSE's Finance and Estates Committee; Chevalier des Arts et Lettres 2025 (GBL release 13 Mar 2025; LSE governance page)

Xavier Likin

Chief Financial Officer

——

GBL press-release contact

Alison Donohoe

Head of Investor Relations

——

GBL press-release contact

Christian Mogge

Investment Partner

——

Led BUKO

Michal Chalaczkiewicz

Investment Partner

——

Led Rayner

Bilge Ogut

Investment Partner

Since January 2026

25 years of investment experience

GBL release, 12 Jan 2026

Michael Ogrinz

Investment Partner

Since January 2026

23 years of investment experience, including 15 at one prior firm (not named in the retrieved excerpt)

GBL release, 12 Jan 2026

Joe Topley

CEO, GBL Capital

Since September 2023

—

GBL Q3 2023 release

Board of Directors

NameRoleNotes

Ian Gallienne

Chairman (since 2 May 2025)

CEO of GBL 2012–2025 (co-MD 2012–2019, sole CEO 2019–2025); son-in-law of the late Albert Frère; architect of the private-asset pivot

Paul Desmarais, Jr.

Vice-Chairman (since 2 May 2025)

Board member since 1990; Chairman 2019–2025; Power Corporation of Canada

Johannes Huth

Managing Director

Executive director

Other directors

Frère- and Desmarais-family representatives, plus independent directors

GBL has a Governance and Sustainable Development Committee, which recommended the 2025 changes, plus customary Audit and Remuneration functions

Board & Management Changes

DateChange

13 Mar 2025

Board announces governance overhaul: Desmarais Jr. to step down as Chairman (becoming Vice-Chairman), Gallienne to become Chairman, Huth to become Managing Director

2 May 2025

Changes effective at the AGM

12 Jan 2026

Appointment of Investment Partners Bilge Ogut and Michael Ogrinz

Early 2026

Technology added as a focus sector

Major Shareholders

HolderStakeSource / comment

Parjointco (50% Frère family group / 50% Power Corporation of Canada)

47.8% voting interest

Power Corporation, "GBL in numbers 2025".

GBL treasury shares

8.0% of capital (10 July 2026)

GBL regulated buyback disclosure

Free float / institutional investors

Remainder

Top-10 institutional holders not publicly disclosed in retrieved sources

Insider ownership (directors personally)

Not publicly disclosed in retrieved sources

Family interests held via Parjointco

Competitive Landscape

Key Competitors

PeerCountryModelRelative positioning vs GBL

Investor AB

Sweden

Wallenberg-controlled holding; listed core plus Patricia Industries (private) plus EQT stake

Benchmark "family holding + private arm"; typically trades at a much narrower discount or a premium

Exor

Netherlands / Italy

Agnelli holding (Ferrari, Stellantis, Philips, etc.)

Larger NAV; high concentration in Ferrari

Industrivärden

Sweden

Listed-only Swedish holding

Pure listed; lower cost

Kinnevik

Sweden

Growth / private tech holding

More venture-like

Wendel

France

Listed holding; pivoting to asset management

Contrasting strategy: Wendel moved into third-party asset management while GBL exited it

Eurazeo

France

Listed private-equity / asset manager

Third-party fee model

Sofina

Belgium

Family holding; growth/VC fund-of-funds

Belgian peer; different risk profile

Ackermans & van Haaren

Belgium

Diversified Belgian holding (marine engineering, banking, real estate)

Belgian peer; operating control model

Peugeot Invest

France

Peugeot-family holding

Smaller

HAL Trust

Netherlands

Family-style holding

Concentrated

CVC, KKR, EQT, Partners Group (sponsors)

Various

Private equity

Competitors for private deals, and partners (CVC)

Peer Comparison FY2025

AttributeGBLInvestor ABExorWendel

Controlling shareholder

Frère–Desmarais (Parjointco, 47.8% voting)

Wallenberg foundations

Agnelli (Giovanni Agnelli BV)

Wendel family (WPS)

Private-asset strategy

Control / co-control, Europe, healthcare and business services

Patricia Industries (100%-owned)

Selective (e.g. healthcare)

Shift to third-party asset management

Third-party asset management

Exiting (Sienna IM sold 2025–26)

EQT stake

Limited

Core growth strategy

Leverage

LTV 0.0% (H1 2026)

Low

Moderate

Moderate

Discount to NAV

27.9% at YE2025; c.18% at €82.5 vs June NAV per share

———

Company Snapshot

1902

Founded

Brussels, Belgium

Headquarters

SWOT Analysis

Strengths

  • Balance sheet. LTV of 0.0% and €4.6bn of liquidity at 30 June 2026, with €2.5bn of undrawn committed lines (GBL H1 2026).
  • Credit quality. Moody's A1 stable, reconfirmed June 2026. Bond demand was strong: the €500m 10-year bond was nearly 6x oversubscribed in January 2026.
  • Healthcare track record. Affidea NAV rose from €1,477m to €2,140m in 2025 (MoIC 1.9x). FY2025 direct private value creation was +€641m.
  • Disposal execution. More than €5bn of disposals were completed ahead of the 2027 deadline (H1 2026).
  • Shareholder returns. €1bn returned in 2025 and €773m in H1 2026. FY2025 TSR was 23.2%.
  • Stable family control. Parjointco's 47.8% voting interest provides a long-term anchor and enables patient capital deployment.

Weaknesses

  • NAV-per-share decline. NAV per share fell from €143.91 (2021) to €100.77 (H1 2026), −30%.
  • Recurring cash yield below the dividend. FY2025 cash earnings of €381m versus a €666m dividend paid; H1 2026 cash earnings fell to €296m from €320m.
  • IFRS losses. €(625)m in FY2025, driven by Imerys (€(225)m) and GBL Capital (€(381)m).
  • Legacy consumer drag. Pernod Ricard −€619m and adidas −€430m in FY2025 fair value.
  • Canyon underperformance. MoIC 0.7x; FY2025 EBITDA −34%.
  • Holding costs and incentives. The carried-interest and LTIP charges totalled €(80)m in FY2025, compared with recurring opex of about €(55)m.

Opportunities

  • Recordati. Co-control of a global rare-disease pharma at about 13x 2025 EBITDA (Mergermarket estimate at €51.29).
  • Further discount compression. From 27.9% toward peer levels, aided by buybacks and cancellations.
  • Buy-and-build platforms. BUKO (Europe-wide TTM) and Rayner (US expansion, Galaxy launch in Q4 2026).
  • Technology sector. Added as a focus area in 2026, widening the opportunity set.
  • Recovery optionality in listed stakes. Pernod targets 3–6% organic growth over FY27–FY29 and adidas high-single-digit growth to 2028.
  • Remaining non-core cash. About €1.7bn of GBL Capital NAV, including €0.5bn of deferred proceeds, is available for redeployment.

Threats

  • Recordati deal friction. Minority dissent (Palliser), independent directors calling the offer inadequate, and the price raised to €53 (Il Sole 24 Ore, Oct 2026).
  • Concentration risk. Healthcare already made up 79% of direct-private NAV at end-2025, and CVC is co-controller in two assets.
  • Imerys. Weak construction and refractory markets led to a €467m impairment and current net income down 44%.
  • Tariffs and trade policy. These affect Pernod, adidas and Canyon.
  • Valuation-mark risk. Private assets are carried at IPEV fair value, and the market discount signals scepticism.
  • Interest-rate and refinancing costs. New debt at 3.75% versus historical lower coupons.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
2 May 2025AGM: FY2024 dividend €5.00 (+82%) approved; Huth appointed Managing Director; Gallienne becomes ChairmanGovernance transition completed
2 May 2025Q1 2025 results: NAV per share €111.17; €110m buybacks in Q1Simplification under way
13 May 2025FY2024 dividend paid€666m cash return
31 Jul 2025H1 2025: NAV €14.4bn, NAV per share €107.75; TSR 16.1%; direct private assets +€441mHealthcare value creation
2 Oct 2025Announcement relating to GBL Capital disposals (referenced in 9M 2025 presentation)Non-core exit
Oct 2025Affidea €150m capital injectionGrowth funding
Oct 2025Umicore sale-and-leaseback of gold inventories (€416m net proceeds), a portfolio-company actionSupported Umicore re-rating before GBL's exit
7 Nov 20259M 2025 results; NAV at 30 Sept 2025 €13.96bn (€104.83 per share)–
Q4 2025Umicore half-stake sale (€299m)Listed simplification
19 Dec 2025Agreements to sell Sienna Gestion and Sienna Private CreditExit from third-party asset management
12 Jan 2026Appointment of Investment Partners Bilge Ogut and Michael OgrinzTeam capacity for deployment
14 Jan 2026€500m 10-year bond at 3.75%, nearly 6x oversubscribedLiquidity and maturity extension
7–9 Feb 2026Rayner: definitive agreements for 45% co-control (€0.5bn)Third healthcare platform
13 Feb 2026Sienna Real Estate disposalNon-core
19 Feb 2026Imerys FY2025: net loss €(409)m on €467m impairmentHit to GBL IFRS result (€(225)m)
25 Feb 2026Umicore full exit (c.8.0%, €0.3bn); total disposals reach €4.8bn (95% of target)Plan nearly complete
12–13 Mar 2026FY2025 results: NAV €14.0bn; TSR 23.2%; dividend proposal €5.125; net result €(625)mStrong TSR, weak IFRS result
Late Mar 2026CVC non-binding approach to Recordati disclosed (26 March)Origin of the Recordati deal
7 Apr 2026Annual Report 2025 published; AGM/EGM convened–
23 Apr 2026BUKO acquisition announcedBusiness-services entry
7 May 2026AGM/EGM: dividend €5.125 approved; 3.4m shares cancelled. Q1 2026: NAV €13.3bn, €99.86 per share; direct private assets 37%–
18 May 2026FY2025 dividend paid (ex-date 14 May)–
22 May 2026CVC and GBL launch €10.7bn (€51.29 per share) voluntary tender for RecordatiLargest healthcare deal of 2026 in Europe (Jefferies)
28 May 2026Rayner closing–
June 2026Moody's confirms A1, stable; Recordati offer document filed with CONSOBCredit strength
8 Jul 2026BUKO closing–
30 Jul 2026H1 2026: NAV €13.08bn (€100.77 per share, −4.4% YTD); cash earnings €296m; net result €53.5m; liquidity €4.6bn; LTV 0.0%; €2.3bn invested across three deals–
25 Aug 2026€500m 8-year bond placed (settled 1 Sept 2026)Pre-funding Recordati
Sept 2026Recordati shares trade above the €51.29 offer; activist Palliser argues for a higher price; independent directors call the offer inadequate (Mergermarket; Il Sole 24 Ore)Deal risk
5–6 Oct 2026Recordati offer raised to €53.00 as "best and final"; acceptance period extended from 15 to 23 Oct; payment on 2 Nov (Il Sole 24 Ore; Zonebourse)Key near-term catalyst
5 Nov 2026 (scheduled)Q3 2026 resultsNext disclosure

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Income Statement

5 charts
Key Financials (FY2021–FY2025): Net asset value fell from EUR 22,501 Mn in FY2021 to EUR 14,035 Mn in FY2025.
Groupe Bruxelles Lambert SA — Key Financials (FY2021–FY2025)
Series (EUR Mn)FY2021FY2022FY2023FY2024FY2025
Net asset value22,50117,77516,67115,68114,035
Cash earnings474416414336381
Consolidated net result, group share279-5851,723132-625
Gross cash excl. treasury shares2,2931,3971,0802,6062,393

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.